0      0

2021 GAPNA Contemporary Pharmacology Conference


ISPT02 - Introducing GEMTESA® (vibegron) 75 mg tablets for the Treatment of Overactive Bladder (OAB) - Urovant


Mar 4, 2021 12:30pm ‐ Mar 4, 2021 1:30pm


Credits: None available.

Free

Description

Introducing GEMTESA® (vibegron) 75 mg tablets for the Treatment of Overactive Bladder (OAB)
An Overview of OAB Implications and Challenges and a New Treatment Option for Long-Term Care

Supported by Urovant Sciences:  This product theater will discuss the clinical profile and prescribing information for GEMTESA® (vibegron) 75mg tablets, for the treatment of Overactive Bladder. The presentation will also review challenges and implications associated with overactive bladder in long term care.

custom image

Speaker(s):

  • Cathy Yaggy, MSN, GNP-BC, Director of Primary Care, Eventus WholeHealth

Credits

Credits: None available.

You must be logged in and own this session in order to post comments.

Print Certificate
Completed on: token-completed_on
Print Transcript
Please select the appropriate credit type:
Number of hours attended:
/
test_id: 
credits: 
completed on: 
rendered in: 
* - Indicates answer is required.
token-content

token-speaker-name
token-index
token-content
token-index
token-content
token-index
token-content
token-index
token-content
token-index
token-content
token-index
token-content
/
/
token-index
token-content
token-index
token-content